R&D

Quote












So, the R&D squad is very small – tight on peeps and working with a shoestring budget. They've been hit with layoffs a bunch, and it's like they're playing catch-up with projects, not just launching new stuff, but also trying to revive old products like dermagraft. Picture this: their budget is practically a startup's pocket change. And let's not forget the hurdles, especially with projects like ReNu needing the BLA nod; it's like a marathon that takes ages and a boatload of cash.

The biopharma game is no joke.biopharma product cycle is lengthy – the R&D peeps are juggling BLA studies, cooking up new products, publishing research, and dancing with FDA requests. But here's the deal – they're doing their best. While resources are tight, management could enhance outcomes by prioritizing key projects and give 'em a hand by honing in on a few key battles. Cut 'em some slack
 






anonymous said:
So… RD over the last 7 years has just released PuraPly with more layers? Neat
Click to expand...

R&D operates with a limited crew and a modest budget. They've been hit with layoffs a bunch, and it's like they're playing catch-up with projects, not just launching new stuff, but also trying to revive old products like dermagraft.
Picture this: their budget is practically a startup's pocket change. And let's not forget the hurdles, especially with projects like ReNu needing the BLA nod; it's like a marathon that takes ages and a boatload of cash.
The biopharma game is no joke – biopharma product cycle is lengthy. The team is spread too thin the R&D peeps are juggling BLA studies, cooking up new products, publishing research, and dancing with FDA requests. management could enhance outcomes by prioritizing key projects. Management could give 'em a hand by honing in on a few key battles. Cut 'em some slack...
 












anonymous said:
R&D operates with a limited crew and a modest budget. They've been hit with layoffs a bunch, and it's like they're playing catch-up with projects, not just launching new stuff, but also trying to revive old products like dermagraft.
Picture this: their budget is practically a startup's pocket change. And let's not forget the hurdles, especially with projects like ReNu needing the BLA nod; it's like a marathon that takes ages and a boatload of cash.
The biopharma game is no joke – biopharma product cycle is lengthy. The team is spread too thin the R&D peeps are juggling BLA studies, cooking up new products, publishing research, and dancing with FDA requests. management could enhance outcomes by prioritizing key projects. Management could give 'em a hand by honing in on a few key battles. Cut 'em some slack...
Click to expand...


Its a set up to show potential partners how advanced we are and you should invest in us. Look at what we have going on. What is the trouble with our company. It isn't R&D! it is the field and the lack of selling our products.
 






anonymous said:
R&D operates with a limited crew and a modest budget. They've been hit with layoffs a bunch, and it's like they're playing catch-up with projects, not just launching new stuff, but also trying to revive old products like dermagraft.
Picture this: their budget is practically a startup's pocket change. And let's not forget the hurdles, especially with projects like ReNu needing the BLA nod; it's like a marathon that takes ages and a boatload of cash.
The biopharma game is no joke – biopharma product cycle is lengthy. The team is spread too thin the R&D peeps are juggling BLA studies, cooking up new products, publishing research, and dancing with FDA requests. management could enhance outcomes by prioritizing key projects. Management could give 'em a hand by honing in on a few key battles. Cut 'em some slack...
Click to expand...
So true. Short sighted execs desperately trying to prop up stock price by slashing budgets and laying off key contributors so they can cash in more executive options. It is a sad state of affairs.
 












anonymous said:
Its a set up to show potential partners how advanced we are and you should invest in us. Look at what we have going on. What is the trouble with our company. It isn't R&D! it is the field and the lack of selling our products.
Click to expand...

Or perhaps we have a huge product line chasing the same patients with each Q Code. There is little diversity on attacking our patient population and very little in the White Paper stance differentiating each product in the market. Its like hey! Let go from PPAM to Nushield to Affinity on the SAME patient. Aaaaand if THAT doesnt close the wound hopefully it is a DFU or VLU where Apligraf is indicated. Very little in nuance on why any works differently than the other. Let alone a million other products out there which is why the spread sale is where its at in driving revenues. Its stale and lame.
 






Top Bottom
Back
Quote